Dynamically Covalent Lipid Nanoparticles for Nonviral CRISPR-Cas9 Genome Editing in Choroidal Neovascularization

Study Background and Research Question

Choroidal neovascularization (CNV), a hallmark of wet age-related macular degeneration (wAMD), is driven by pathological angiogenesis resulting from overexpression of vascular endothelial growth factor A (VEGFA) in retinal pigment epithelial (RPE) cells. Current front-line therapies involve frequent intravitreal injections of anti-VEGF agents, which suffer from incomplete response rates, substantial patient burden, and notable risks of ocular complications (paper). While adeno-associated virus (AAV)-mediated CRISPR-Cas9 genome editing has shown promise for sustained VEGFA suppression, the immunogenicity of viral vectors and concerns over persistent Cas9 expression limit clinical translation. Thus, the central research question addressed in Cao et al. is: can a nonviral, biodegradable nanoparticle system transiently deliver Cas9 mRNA and sgRNA to RPE cells, achieving efficient and safe genome editing for CNV therapy?

Key Innovation from the Reference Study

The major innovation of this work is the development of lipid nanoparticles (LNPs) incorporating dynamically covalent iminoboronate ester linkages in their cationic lipidoid component, enabling both high mRNA transfection efficiency and stimulus-responsive cargo release. Specifically, the authors synthesized a library of lipidoids using a streamlined "one-pot" approach, screening for optimal properties. The top candidate, A4B3C7, forms LNPs (LNP-A4B3C7) that remain stable extracellularly but undergo rapid degradation in the oxidative (H₂O₂-rich) environment of diseased RPE cells, resulting in efficient endosomal escape and cytosolic release of Cas9 mRNA and VEGFA-targeting sgRNA (paper). This dynamic covalent chemistry addresses critical limitations of conventional LNPs: inefficient cytosolic mRNA release and potential cytotoxicity from persistent cationic charges.

Methods and Experimental Design Insights

The research team engineered and characterized a suite of iminoboronate-linked lipidoids, using systematic structural variations to tune physicochemical and biological properties. High-throughput screening identified A4B3C7 as the optimal candidate, based on its ability to form stable LNPs with high encapsulation efficiency for both Cas9 mRNA and sgRNA. The LNPs were evaluated for size, charge, and degradability under oxidative stress, simulating the diseased cellular environment. For functional validation, the authors delivered mCas9/sgVEGFA complexes via LNP-A4B3C7 into mouse RPE cells in vitro and by single intravitreal injection in a laser-induced CNV mouse model. Outcomes included genome editing efficiency (assessed by T7E1 assay and sequencing), VEGFA protein suppression (ELISA), reduction in CNV lesion area (fluorescein angiography and histology), and comparison to benchmarked anti-VEGF drug performance.

Protocol Parameters

• assay | mRNA concentration in LNPs | 1 mg/mL | Ensures sufficient Cas9 mRNA for robust genome editing in RPE cells | paper
• assay | 5'-capped mRNA structure | Cap 1 | Promotes efficient translation and reduced innate immune activation | workflow_recommendation
• in vivo delivery | Intravitreal injection volume | 2 μL | Minimizes ocular toxicity and ensures local distribution | paper
• assay | sgRNA:Cas9 mRNA ratio | 2:1 (molar) | Optimizes targeting and editing efficiency | paper
• in vivo imaging | Time to peak editing effect | 3-7 days post-injection | Aligns with transient mRNA translation and protein turnover | paper
• translation efficiency assay | Use of modified uridines (e.g., 5-moUTP) | recommended | Enhances mRNA stability, translation, and immune evasion | workflow_recommendation

Core Findings and Why They Matter

The dynamically covalent LNP-A4B3C7 system achieved the highest mRNA transfection efficiency among tested candidates in RPE cells, attributed to its oxidative-triggered disassembly and efficient cytosolic release of nucleic acids. Single intravitreal administration of mCas9/sgVEGFA-LNPs resulted in substantial VEGFA gene disruption and a pronounced decrease in CNV area compared to both untreated controls and clinical anti-VEGF drug recipients (paper). Importantly, the therapeutic effect was more sustained and was associated with minimal detectable immunogenicity or local cytotoxicity, underscoring the biocompatibility advantage of nonviral, transient mRNA delivery. This approach also circumvents the drawbacks of traditional lipid-based transfection reagents (e.g., Lipofectamine), which can induce cytotoxicity due to permanently charged lipids. These findings are highly relevant for researchers focused on mRNA delivery for gene expression applications, as they validate the potential for nonviral LNP systems to mediate precise genome editing in challenging tissues such as the eye. Furthermore, the work exemplifies the utility of translation efficiency assays and in vivo imaging with fluorescent mRNA reporters to monitor delivery, expression, and therapeutic outcomes.

Comparison with Existing Internal Articles

Several internal resources discuss the advantages of advanced mRNA constructs for gene delivery and functional readouts:

• The article "Next-Generation mRNA Tools: Mechanistic Mastery and Strategy" analyzes how innovative capping, 5-methoxyuridine modification, and poly(A) tail design—as featured in EZ Cap™ EGFP mRNA (5-moUTP)—enhance translation, stability, and immune evasion. These principles directly support the rationale for using similar modified mRNAs in LNP-based delivery systems as described in the reference study.
• "EZ Cap™ EGFP mRNA (5-moUTP): Mechanisms, Immunology & Translation" explores the suppression of RNA-mediated innate immune activation through Cap 1 structures and 5-moUTP modifications, paralleling the reference study's goal of minimizing immune responses during mRNA-driven genome editing.

These articles reinforce the mechanistic underpinnings of the dynamically covalent LNP approach, highlighting the synergy between advanced nanoparticle delivery and next-generation synthetic mRNAs for gene expression studies and translation efficiency assays.

Limitations and Transferability

While the dynamically covalent LNPs demonstrated robust efficacy and safety in the mouse CNV model, several limitations warrant consideration:

• Species-specific immune responses and anatomical differences may impact translation to human ocular therapy (paper).
• The optimization of LNP composition and mRNA modifications (e.g., incorporating 5-moUTP or Cap 1 structures) for other tissues or gene targets remains to be systematically explored (workflow_recommendation).
• Long-term off-target effects and durability of genome editing require further longitudinal studies.

Nevertheless, the underlying design principles—stimulus-responsive LNP disassembly, use of capped and modified mRNA, and transient, biocompatible delivery—are highly transferable to other scenarios involving mRNA delivery for gene expression, translation efficiency testing, and in vivo imaging with fluorescent mRNA reporters.

Research Support Resources

Researchers aiming to replicate or extend these workflows, including translation efficiency assays, gene regulation studies, or in vivo imaging with fluorescent mRNA, can consider using EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016). This reporter mRNA, available from APExBIO, features Cap 1 capping, 5-methoxyuridine modification, and an optimized poly(A) tail, providing enhanced stability, reduced immunogenicity, and reliable expression for mRNA delivery and gene expression studies (source: product_spec; workflow_recommendation). Careful adherence to recommended handling and transfection protocols will support robust and reproducible results in both in vitro and in vivo applications.